Engineered immune cells take on multiple Hard-to-Treat cancers

NCT ID NCT04044859

First seen Feb 13, 2026 · Last updated May 01, 2026 · Updated 5 times

Summary

This early-phase study tests a personalized cell therapy (ADP-A2M4CD8) for people with advanced cancers like lung, ovarian, or melanoma that have a specific marker called MAGE-A4. The treatment uses the patient's own immune cells, modified to better attack the cancer, and is given alone or with standard immunotherapy drugs. The main goals are to check safety and find the right dose, while also seeing if tumors shrink.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Clinica Universitaria de Navarra

    Pío, Pamplona, 31008, Spain

  • Duke University Medical Center, Duke Cancer Institute

    Durham, North Carolina, 27710, United States

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Hospital Clinico de Valencia

    Ibanez, Valencia, 46010, Spain

  • Hospital Universitario 12 De Octubre

    Madrid, Avenida de Cordoba S/n, 28041, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, 28040, Spain

  • Hospital Universitario HM Sanchinarro CIOCC

    Madrid, 28050, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, 41013, Spain

  • M.D. Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Name of Institution: Orlando Health Cancer Institute

    Orlando, Florida, 32806, United States

  • OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73104, United States

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • Washington University - School of Medicine

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.